Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Triamcinolone acetonide + hydrocortisone is a combination of two topical corticosteroids used to relieve inflammation, itching, redness, and discomfort associated with various skin conditions such as eczema, psoriasis, and allergic reactions. Both agents act by suppressing the inflammatory response and immune activity in the skin. Triamcinolone acetonide is considered a medium to high potency corticosteroid, while hydrocortisone is classified as low to medium potency. The combination may be used when a broader range of anti-inflammatory effects or stepwise therapy is desired. These drugs are available in multiple formulations (cream, ointment, lotion) and are typically applied directly to affected areas of the skin[1][4][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on triamcinolone acetonide + hydrocortisone.